News Chart Galecto, Inc.

Equities

GLTO

US36322Q1076

Delayed Nasdaq Other stock markets 03:44:49 2024-06-04 pm EDT			5-day change	1st Jan Change
0.56 ^USD	-9.53%		-8.18%	-20.53%

May. 01	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI
Apr. 29	Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

7de2be9ed99c700d910.cpKhwN1qX_zco__acDQgnSG1B4UyegmDS4RR1owgYVU.A8r3tuQCD6OP4Ja_R3VF20DnMLB1OWPoIuJpntsNGxNL08qvnFkeu_HSiA~d29ead499039766a5b3667782017b53a